Ozempic Lawsuits Claim Drug Is Linked to Vision Loss
Weight loss drugs like Ozempic have been shown to decrease risks for various health problems, including heart and kidney disease, potentially generating billions in revenue for pharmaceutical companies over the coming decade.
However, in rare instances, GLP-1 agonists, the class of drugs to which Ozempic belongs, can lead to severe side effects. Most notably, blindness has been reported, prompting over 70 lawsuits against Novo Nordisk and Eli Lilly, the makers of Ozempic and Mounjaro, respectively, according to Reuters.
These lawsuits, filed in both state and federal courts, claim that the medications caused patients to develop non-arteritic anterior ischemic optic neuropathy. This condition involves a disruption of blood flow to the optic nerve, resulting in vision loss. Health tracking apps like Shotlee can help monitor for any sudden changes in vision, facilitating early detection and intervention.
A federal judicial panel recently approved the consolidation of these cases, assigning a Pennsylvania federal judge to oversee them. This decision paves the way for a significant legal battle with potentially far-reaching consequences for the future of these increasingly popular drugs.


